GRIPPER / Gynecologic screening — UKCTOCS: What the Ovarian Cancer Trial Found

What the trial set out to test

Ovarian cancer is usually found late, and that is the whole reason anyone tried screening for it. The UK Collaborative Trial of Ovarian Cancer Screening, UKCTOCS, was built to answer one question: does screening the general population cut deaths from the disease?

It is one of the largest screening trials ever run. Between April 2001 and September 2005, 1,243,282 women were invited and 202,638 took part. All were postmenopausal, aged 50 to 74, recruited from 13 NHS centers in England, Wales, and Northern Ireland. Women who had already had both ovaries removed, who had a previous or active cancer, or who were at raised familial risk were excluded.

Participants were randomly assigned in a 1:1:2 ratio to one of three groups:

• Yearly multimodal screening: a CA-125 blood test read through the Risk of Ovarian Cancer Algorithm, with ultrasound used as a second step
• Yearly transvaginal ultrasound alone
• No screening

The primary outcome was death from ovarian or fallopian tube cancer. That choice matters, and the trial is now the standard example of why.

What it found

Follow-up ran to a median of 16.3 years. Over that time, 2,055 women were diagnosed with ovarian or tubal cancer: 522 in the multimodal group, 517 in the ultrasound group, and 1,016 among those not screened.

Screening did shift the stage at which cancers were found. The multimodal group had 47.2% more stage I cancers than the unscreened group and 24.5% fewer stage IV cancers. Taken together, stage I or II disease was 39.2% more common in the screened group, and stage III or IV disease 10.2% less common.

Then the mortality result. In total 1,206 women died of the disease: 296 in the multimodal group, 291 in the ultrasound group, and 619 in the unscreened group. Adjusted for group size, all three rates were 0.6%. Neither method significantly reduced deaths. NCI records the hazard ratios as 0.94 for multimodal screening and 0.94 for ultrasound alone, with confidence intervals crossing 1 in both cases.

The trial authors drew the lesson themselves. The shift toward earlier-stage disease was not enough to translate into lives saved, and general population screening cannot be recommended.

Why earlier is not the same as better

Two things can make screening look like it works when it does not.

Lead-time bias moves the diagnosis date earlier without moving the death date. A woman finds out five years sooner and appears to survive five years longer, while nothing about her life has changed.

Length bias favors slow-growing tumors. Screening at fixed intervals is more likely to catch cancers that sit around than cancers that appear and spread between tests. The screened group therefore fills up with the milder cases.

Both distortions inflate survival statistics and stage distributions. Neither touches the number of people who die. That is why mortality was the primary outcome here, and why the earlier-stage finding did not rescue the result.

What screening costs when it does not help

NCI's health-professional summary sets out the harms, drawn from randomized evidence.

Screening produces false positives, and false positives lead to surgery on healthy ovaries. In one trial, 9.6% of screened women had a false-positive result and 6.2% went on to surgery, with a surgical complication rate of 1.2% across all screened women. Oophorectomy rates ran at 85.7 per 10,000 person-years among screened women against 64.2 among those receiving usual care.

Within UKCTOCS itself, the ultrasound-only arm produced 50 false-positive operations per 10,000 screens. The multimodal arm produced 14. Screening complications overall were under 1% for both strategies.

None of that would matter much if screening saved lives. Because it did not, these are costs with nothing on the other side of the ledger. Our page on the benefits and harms of screening covers how that balance is weighed generally.

The numbers behind the urgency

The American Cancer Society projects 21,010 new US cases of ovarian cancer in 2026 and 12,450 deaths, the pair of figures SEER's Stat Facts page carries. Five-year relative survival across all stages, for cases diagnosed in 2016 through 2022, is 52.0%. The median age at diagnosis is 63.

Stage drives the outcome. About 22% of cases are found while still confined to the ovary, with five-year relative survival of 91.9%. Another 18% are found in nearby lymph nodes, at 70.1%. But 54% — more than half — are only found after spread to distant organs, at 31.5%.

That distribution is exactly why screening looked so attractive, and exactly why the null result was so disappointing.

When to get checked

There is no screening test for ovarian cancer in average-risk women. That makes symptoms the route, and ovarian cancer symptoms are vague enough to be dismissed. The pattern that matters is new, persistent, and frequent — roughly more than twelve times a month:

• Bloating or a swollen abdomen that does not settle
• Feeling full quickly, or losing appetite
• Pelvic or abdominal pain
• Needing to pass urine more often or more urgently
• Unexplained weight loss, or unusual tiredness
• Any bleeding after menopause, which needs an appointment on its own

Women at high inherited risk, including BRCA1 and BRCA2 carriers, were excluded from UKCTOCS. Their surveillance and risk-reducing options are a separate conversation, and one for a specialist. Our page on ovarian cancer symptoms covers what an assessment involves.

What to keep in perspective

• The result applies to average-risk postmenopausal women. Women at high inherited risk were excluded and are not covered by it.
• Screening used the technology and CA-125 algorithms of 2001 to 2005. A null result does not rule out a better future test.
• Finding more early-stage cancer is not proof that screening helps. This trial is the clearest demonstration of that gap.
• Screening carries real costs: false alarms, operations on healthy ovaries, and their complications.
• Nothing here replaces a clinician's judgment about a specific symptom or a specific family history.

Sources

• Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182-2193 (PMID 33991479) — https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=33991479&retmode=xml
• NCI PDQ, Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Screening (Health Professional Version) — https://www.cancer.gov/types/ovarian/hp/ovarian-screening-pdq
• NCI, Ovarian, Fallopian Tube, and Primary Peritoneal Cancer—Patient Version — https://www.cancer.gov/types/ovarian
• SEER Cancer Stat Facts, Ovarian Cancer — https://seer.cancer.gov/statfacts/html/ovary.html
• American Cancer Society, Cancer Facts & Figures — https://www.cancer.org/research/cancer-facts-statistics.html

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.